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Purpose: To compare the combined intracavitary/interstitial 
brachytherapy (IC/IS) with intracavitary brachytherapy alone 
(IC) in cervical cancer treated with definitive radio-
chemotherapy and MRI guided adaptive brachytherapy (BT) 
within the EMBRACE study and the impact on target dose, OAR 
dose and late morbidity. 
Methods and Materials: The EMBRACE database containing 1129 
cervix cancer patients enrolled in the study with treatment 
completed before 09/2014 was used for this study. Patients 
having a MRI based parametrial infiltration status (PI) at time of 
BT (n = 999) were divided according to their PI status at first BT: 
no PI (456 patients), proximal PI (412 patients) and distal + pelvic 
wall PI (122 patients). Patients in each group were compared 
according to the use of IC or IC/IS during the course of their 
treatment, to dose in the HRCTV, OARs, and to late morbidity. 
T-test was performed on target and OAR doses (all EQD2 with 
α/β of 10 and 3 Gy) and Chi-square test was performed on 
patients’ characteristics variables. Univariate analysis of 
morbidity Grade 2 and more (G2≤) (rectum, bladder, bowel, 
vagina, overall morbidity) was performed with actuarial 
probabilities based on Kaplan-Meier statistics. 
Results: The median follow up was 23 and 26 months for the IC/IS 
and IC group, respectively. IC/IS patients with proximal PI had 
significantly less G2≥ bladder (19% versus 28%, p = 0.014), bowel 
(10% versus 22%, p = 0.002) and overall morbidity (51% versus 
68%, p = 0.003) at three years, but no difference in G2 ≥ rectal 
and vaginal morbidity. A significant dose decrease was found for 
bowel D2cm3 in the IC/IS group in comparison to the IC group (61 
± 8 Gy versus 63 ± 10Gy) while the same mean dose (D90) to the 
HRCTV was given. Rectal and bladder D2cm3 was not significantly 
different. Patients with distal or pelvic wall PI experienced less 
rectal (13% versus 46%, p = 0.001) and bowel (13% versus 40%, p 
= 0.054) morbidity G2≥ at three years in the IC/IS group in 
comparison to the IC group while bladder and vaginal toxicities 
were not significantly different. Patients in the IS/IC group 
received a significantly higher HR CTV D90 (87 ± 9 Gy versus 80 ± 
13 Gy, p < 0.001). 
Conclusions: These results demonstrate that regardless of the 
extent of PI, the dosimetric and clinical advantages of combined 
intracavitary/interstitial brachytherapy compared to 
intracavitary brachytherapy alone are substantial. IC/IS 
brachytherapy allows for a significantly higher HRCTV D90 (7Gy) 
in patients with distal and pelvic wall PI than IC brachytherapy 
while leading to less rectal and bowel morbidity. For patients 
with proximal PI, the use of IC/IS brachytherapy was associated 
with less bladder, bowel and overall morbidity while allowing for 
the same target dose. Potential biases induced by treatment 
related factors still have to be addressed in a multivariate 
analysis. A more systematic use of IC/IS brachytherapy in cervix 
cancer patients with PI is therefore recommended, especially for 
OAR sparing and for increase of dose to the HRCTV. 
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Purpose: To report on the five-year efficacy results of patients 
with localized high-risk prostate cancer treated with a 
concomitant hypofractionated IMRT boost (simultaneous 
integrated boost) along with adjuvant androgen deprivation 
therapy (ADT). 
Methods and Materials: From 2004-2010, a prospective Phase I-
II study was conducted in patients with any one or more of the 
following: T3 disease, PSA > 20 ng/mL, or Gleason score 8-10. A 
dose of 45 Gy in 25 fractions was delivered to the pelvic lymph 
nodes along with a concomitant IMRT boost of 22.5 Gy to the 
prostate, resulting in a total dose of 67.5 Gy in 25 fractions to 
the prostate over five weeks. Adjuvant ADT was to be delivered 
for two to three years. Biochemical failure was determined by 
the Phoenix definition. Univariate and multivariate analyses 
were performed to look for predictive factors. A post-treatment 
prostate biopsy was to be performed at five years to assess for 
pathologic local control. 
Results: Two hundred and thirty patients were treated and 
followed for the primary five year efficacy endpoint. Patients not 
lost to follow up have a minimum follow up of five years. Median 
age of patients was 72 years. Sixty-seven percent had GS 8-10, 
44% had PSA > 20 ng/mL, and 27% had T3 disease. The median 
duration of ADT was 30.4 months. 79% received at least 18 
months of ADT. The median PSA nadir was 0.02 ng/mL. 92% 
achieved a testosterone nadir of < 0.7 nmol/L. Five year 
probability of testosterone recovery (> 1.7 nmol/L) was 53.9%. 
Five year biochemical control rate was 83.7%. Five year overall 
survival was 93.7%. PSA nadir < 0.5 ng/mL independently 
predicted for higher biochemical control (HR 0.014; p < 0.0001), 
while a PSA nadir < 0.1 ng/mL independently predicted for longer 
overall survival (HR 0.129; p = 0.0024). Starting ADT in an 
adjuvant fashion (versus neoadjuvant) independently predicted 
for higher biochemical control (HR 0.419; p = 0.0116). ADT for ≤ 
12 months independently predicted for worse overall survival 
compared to ADT for > 24 months (HR 6.667; p = 0.014). Of the 
45 patients who underwent a five year prostate biopsy, five 
(11.1%) had a positive result showing malignant cells with no 
radiation effect. The biochemical control and overall survival of 
patients who had a post-treatment biopsy were not different 
from those without a biopsy. Five year actuarial incidence of 
Grade ≥ 3 GI and GU toxicities were 1.9% and 7.2%, respectively. 
Conclusions: A concomitant hypofractionated IMRT boost 
delivering 67.5 Gy in 25 fractions to the prostate over five weeks 
combined with elective pelvic nodal irradiation and adjuvant 
ADT resulted in favourable five year biochemical control and 
overall survival rates for patients with localized high-risk 
prostate cancer. Lower PSA nadir predicted for higher 
biochemical control and longer overall survival. ADT duration of 
≤ 12 months was associated with decreased overall survival. 
Pathologic local failure rate as assessed by five-year post-
treatment biopsy was low. 
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Purpose: Serum LDH level is incorporated in the stage 
classifications of lymphoma, melanoma, and seminoma. Recent 
series have also shown it to be prognostic for nasopharyngeal 
cancer. We evaluated the prognostic value of pre-radiotherapy 
(pre-RT) LDH in HPV-related (HPV+) and unrelated (HPV–) non-
metastatic oropharyngeal cancer (OPC). 
Methods and Materials: All newly diagnosed p16-confirmed HPV+ 
and HPV– OPC patients receiving IMRT +/- chemotherapy from 
2005-2013 were reviewed. Pre-RT LDH level was recorded as a 
binary variable [elevated (E) versus non-elevated (NE)]. Overall 
survival (OS) and relapse-free survival (RFS) were compared 
between LDH E versus NE by HPV status. Multivariable analyses 
(MVA) assessed the prognostic value of LDH on OS and RFS overall 
and in the subset with normal liver function (by AST/ALT/ALP). 
Recursive partitioning analysis (RPA) created prognostic groups 
in HPV+ OPC combining TNM and LDH. 
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Results: Of 939/1077 (87%) HPV tested OPC, LDH level was 
available in 611/678 (90%) HPV+ and 225/261 (86%) HPV–. Median 
follow up was 4.4 and 4.1 years for the HPV+ and HPV– cohorts, 
respectively. Among HPV+, LDH E (n = 223) versus NE (n = 388) 
cases comprised older age (median 60 versus 58 years, p = 0.02) 
and slightly larger primary tumour volume (GTV) (median 24 
versus 21 cc, p = 0.08) but similar T (p = 0.27) and N-category 
(p=0.34), smoking pack-years (sPY) (p = 0.27), and alcohol 
consumption (p = 0.25). A lower three-year OS (79% versus 87%, 
p < 0.01) and RFS (79% versus 89%, p  < 0.01) were found in HPV+ 
LDH E versus NE. MVA for HPV+ patients confirmed that LDH-E 
increased risk of death [HR 1.5 (1.1-2.2), p = 0.03] and relapse 
[HR 1.8 (1.2-2.7), p < 0.01) after adjusting for sPY (OS: p < 0.01; 
RFS: p = 0.94), age (OS: p = 0.09; RFS: p = 0.63), T3-4 (OS: p = 
0.02; RFS: p = 0.48), N2c-3 (OS: p = 0.08; RFS: p < 0.01), GTV-1° 
(OS: p < 0.01; RFS: p < 0.01) and chemotherapy (OS: p < 0.01; 
RFS: p = 0.02). The prognostic significance of LDH-E was 
confirmed by MVA within the subset of HPV+ patients with normal 
liver function [OS: HR 1.7 (1.1-2.7), p = 0.01; RFS: 2.0 (1.3-3.3), 
p < 0.01]. RPA divided HPV+ OPC into low-risk (T1-3N0-N2c_LDH-
NE) and high-risk (T4 or N3 or T1-3N0-N2c_LDH-E) subgroups. The 
three-year OS was 91% versus 72% and RFS was 91% versus 75%, 
respectively (both p < 0.01). In the HPV– cohort, no differences 
were found in baseline characteristics or outcomes between LDH 
E (n = 86) and NE (n = 139) cases (three-year OS: 59% versus 52%, 
p = 0.96; RFS: 68% versus 68%, p = 0.91), and the non-prognostic 
effect was confirmed by MVA (OS: HR 1.2, p = 0.43; RFS: HR 1.1, 
p = 0.54) 
Conclusions: This study shows that pre-RT serum LDH elevation 
is prognostic for HPV+ OPC independent of liver function but non-
prognostic for HPV– patients. LDH has the potential to be 
included in HPV+ prognostic groupings, similar to other tumours. 
T1-3N0-N2c HPV+ OPC with elevated LDH appears associated 
with increased risk of death and disease relapse comparable to 
T4 or N3 subsets 
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Purpose: Breast-conserving surgery followed by adjuvant 
radiation therapy (RT) is the standard treatment for early-stage 
breast cancer (EBC). Up to 30% of patients experienced moist 
desquamation or ≥ Grade 2 skin toxicity following standard 
fractionation tangent field 3D-conformal radiotherapy (3D-CRT). 
The feasibility of skin-sparing helical tomotherapy (SSHT) by 
configuring skin as an organ at risk (OAR) was established in an 
earlier dosimetric study. The aim of this study was to assess 
whether SSHT would reduce the incidence of ≥Grade 3 acute skin 
toxicity in EBC patients undergoing RT. 
Methods and Materials: This single institution Phase III 
randomized control trial comparing SSHT to 3D-CRT for RT in EBC 
patients with acute skin toxicity as the primary endpoint. The 
skin as OAR was defined as a 5 mm strip of ipsilateral breast skin 
and we employed a constraint on the skin volume receiving dose 
up to 40 Gy while delivering dynamic IMRT as described earlier. 
Patients were assessed weekly during RT and then at six and 12 
weeks post-RT. Acute toxicity parameters recorded were level of 
skin erythema, radiation dermatitis, and pain. 
Results: During the period of May 2008 to January 2012, 177 EBC 
patients were enrolled into the study and 90 were randomized to 
3D-CRT arm and 87 to SSHT. The mean age was 59 years. SSHT 
achieved more homogenous coverage of the target than 3D-CRT. 
HT arm had lower proportion of acute toxicity. The incidence of 
erythema and moist desquamation were significantly higher in 
the 3D-CRT arm than in the SSHT treated arm (erythema: 60% 
versus 39%; p = 0.005; moist desquamation: 33% versus 11%; 
P=0.0003). No patients in the SSHT arm had exudate while 11% 
of patients in the 3D-CRT arm did (0% versus 11%; p = 0.0014). 
Patients in the 3D-CRT arm had increased incidence of ≥ Grade 3 
tenderness and discomfort of breast (tenderness: 54% versus 24%; 
p < 0.0001, discomfort: 9% versus 1%; p = 0.019), but ≥ Grade 3 
itching, burning and pulling were not significantly different 
between the treatment arms. The independent prognostic 
factors that contributed significantly to acute toxicity in the 
multivariate analysis were large breast volume, adjuvant 
chemotherapy, and 3D-CRT. 
Conclusions: SSHT significantly reduced the incidence of moist 
desquamation compared with 3D-CRT. Incidence of acute 
toxicity was correlated with large breast volume, adjuvant 
chemotherapy, and 3D-CRT. Combining an IMRT approach with 
explicit reduction in skin dose may further improve both acute 





THE ROLE OF STEREOTACTIC BODY RADIATION THERAPY (SBRT) 
IN GYNECOLOGICAL CANCERS: A SYSTEMATIC REVIEW 
Lucas C. Mendez1, Eric Leung2, Patrick Cheung2, Lisa Barbera2 
1University of São Paulo, São Paulo, Brazil 
2University of Toronto, Toronto, ON 
Purpose:  SBRT is an effective treatment that delivers highly 
conformal doses of radiation to target volumes, sparing normal 
organs. Despite the advancements in this technique for other 
disease sites, its role in gynecological cancers remains unclear. 
This systematic review aims to evaluate toxicity and outcomes 
of SBRT in gynecological malignancies. 
Methods and Materials: In accordance to PRISMA guidelines, 
a systematic review of the literature was conducted on 
studies reporting SBRT in gynecological malignancies. EMBASE, 
MEDLINE and Cochrane databases were systematically 
searched for relevant studies until October 2015. All 
relevant studies evaluating the role of local-regional SBRT 
for gynecological malignancies (excluding CNS, extra-pelvic 
and extra-para-aortic lesions) were included. Relevant data 
regarding toxicities and outcomes were abstracted and 
analyzed. 
Results: From 534 references, 23 articles from 2004 to 2015 were 
selected, comprising a total of 382 patients. Studies were 
classified into six categories: 1) Radical treatment with SBRT as 
local boost for cervix tumours: total of 34 patients were 
identified in seven studies. Treated PTV median volume (MV) 
ranged from 41 to 146 mL and local control (LC) from 0 to 100% 
in a median follow up time of 4 to 22 months. Gastro-intestinal 
(GI) G3/4 toxicity was ~12%. 2) Radical treatment with SBRT as 
a local boost for endometrial cancer: 13 patients found in three 
studies. Eighty-five percent of the patients were from one series 
reporting a 55% LC at 18 months. G3 GI toxicity was reported in 
one out of 13 patients. 3) SBRT to lymph node metastases: 197 
patients were found in seven studies. Treated PTV-MV ranged 
from 16 to 42 mL and LC 60-100% in a range of median follow up 
time of 14-20 months. Long-term G3/4 GI and genito-urinary 
(GU) toxicity was 3% and 0.005%, respectively. 4) Pelvic 
recurrences treated with SBRT: Majority received a course of 
radiotherapy before, either as a previous treatment or as first 
course on salvage attempt. Seventy-two patients were found in 
10 studies. Treated PTV-MV ranged from 20 to 154 mL and LC 
from 51% to 100% in a median follow up range of 4-22 months. 
Chronic G3/4 GI and GU toxicity were 22% and 1.5%, respectively. 
5) Adjuvant treatment with SBRT to the vaginal vault after EBRT:
61 patients were found in three studies. LC was 91-92% (1-11 
years) and GI G3 toxicity was 3%. 6) Two studies included two 
